Chronic pain: the burden of disease and treatment innovations

S. Monti, R. Caporali
Unità Operativa Complessa di Reumatologia, IRCCS Fondazione S. Matteo, Pavia. Università di Pavia

SUMMARY
Musculoskeletal conditions are the most frequent cause of chronic pain and affect around 1 in 5 adults in Europe. When chronic pain occurs, it becomes disease itself, with substantial clinical, social and economic impact. Efficacy and tolerability problems are encountered with all therapeutic strategies available to treat musculoskeletal pain. This often limits effective analgesia and patients’ long term compliance, with the result that chronic pain is persistently underestimated and undertreated. Tapentadol is a novel, centrally acting analgesic that has been recently commercialized for the treatment of chronic pain. This new molecule, by combining two distinct mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), introduces a new pharmacological class called MOR-NRI. Several studies demonstrated promising results in the management of both nociceptive and neuropathic pain and good tolerability profile, particularly concerning side effects, compared to traditional opioids. This novel analgesic represents a possible therapeutic option also in the rheumatologic field, particularly in the treatment of osteoarthritis and low back pain.

Key words: musculoskeletal diseases, chronic pain, opioids, tapentadol.
up to one-half low back pain in a 1-month period (7). A survey on different health aspects in the European Union, the “Eurobarometer Report on Health” (1,8), included a question on musculoskeletal pain. As many as 32% of all respondents and 44% of those 55 years and over reported to have experienced muscle, joint, neck or back pain affecting their daily activities in the previous week. Up to 25% of all respondents reported chronic restrictive musculoskeletal pain lasting more than 3 months at some point in their life. A lower educational profile and female sex were risk factors for developing musculoskeletal pain (1,8). In 2008 a questionnaire conducted by the National Health and Wellness Survey on 53,525 adults in five European countries (United Kingdom, France, Spain, Germany and Italy) revealed that 22% of the subjects had suffered from pain within the last month, of whom 44% experienced pain daily (9). Back pain was the commonest condition causing chronic pain (71%), followed by joint pain, while oncologic pain accounted for only 1% of the patients. Pain severity correlated with the general health and mental status, with high incidence of depression (35%), anxiety (42%) and sleep difficulties (58%) compared to the general population (2, 9).

The burden of chronic musculoskeletal pain is relevant, often leading to functional disability and potentially to severe impairment of normal daily living activities. About one third of the Italian population is reported to have sought medical advice for musculoskeletal complaints in the previous year (10). OA is the most common joint disorder and accounts for more disability among the elderly than any other disease (1). Health related quality of life (HRQOL) of older patients with OA has been reported to be lower than that of the community-matched cohort and similar to scores from patients with depression or advanced cancer (1). OA is listed among the leading causes of burden of disease expressed in DALYs in Europe. One DALY can be defined as the loss of 1-year of healthy life. DALYs are calculated as the sum of the years of healthy life lost owing to premature mortality (YLL) and the years lived with disability (YLD) (1). The MAPPING study evaluating the quality of life in patients with musculoskeletal diseases demonstrated that severe chronic pain (grade III and IV), associated with high disability, was reported more commonly in the inflammatory rheumatologic diseases (22.7%), followed by the low back pain (12.6%) group, and was significantly lower in patients with osteoarthritis and soft tissue disorders (11). This study also demonstrated a significant correlation between pain intensity and health status evaluated with the short form (SF-36) questionnaire (11).

TREATMENT OVERVIEW: THE NEED FOR NEW THERAPEUTICAL OPTIONS

From the previously mentioned evidence, it is clear that chronic pain has a substantial medical and social impact. Optimal management of OA requires a combination of non-pharmacological and pharmacological modalities. Initial treatment should focus on non-pharmacological approaches (eg, lifestyle, physical therapy). For patients whose symptoms are not controlled by these approaches, pharmacological treatments should then be considered (12). Nevertheless, data focusing on the pharmacologic prescription modalities of general practitioners and specialists do not reflect the importance of an effective treatment of chronic pain.

An insight of the epidemiology of musculoskeletal disorders in Italy revealed that at least 25% of the 48,136,832 Italians aged over 18 years (2006 census) report musculoskeletal disorders, but nearly 40% don’t seek any medical attention and only 4% of them are followed by rheumatologists (13). The American Academy of Pain Medicine estimates that more than 4 every 10 patients with moderate-to severe pain don’t get adequate relief from analgesics; a quarter of patients change health care professionals more than once because of perceptions of suboptimal pain care (14). Data from the AMICA study analysing pharmacologic and non-pharmacologic prescription patterns of general practitioners and specialists
to treat symptomatic OA suggest that a consistent number of patients don’t receive any treatment at all, while the majority of them are treated with mild analgesics, NSAIDs or coxibs (10). In the latest years, we are assisting to a decline in the use of NSAIDs to treat OA pain. This particularly affects elderly patients, in spite of the higher prevalence of musculoskeletal chronic pain in this population. The descending trend is probably due to the increasing awareness of potential side effects of NSAIDs, particularly affecting the gastrointestinal system, in the setting of often multipathological, complex patients (15). A striking decrease in the use of coxibs was also registered after rofecoxib withdrawal from the market due to the evidence of an increased risk of myocardial infarction (16). An Italian study analysing the effect on drugs prescription after rofecoxib withdrawal showed a reduction in coxib use from 4.4% to 1.6%. A very low prevalence of weak opioids prescription (0.4%) was also reported (16). The American Geriatrics Society recommendations suggest that acetaminophen should be the first choice pharmacotherapy in the elderly; NSAIDs and COX-2 selective inhibitors may be considered rarely, and with extreme caution, in highly selected individuals. These patients should routinely be assessed for GI and renal toxicity, hypertension, heart failure. Patients with moderate to severe pain, pain-related functional impairment, or diminished quality of life because of pain should be considered for opioid therapy (17). Surprisingly, despite guidelines recommendations, the reduced prescription rate of anti-inflammatory drugs was not followed by an increase in the use of different medications with proved efficacy, such as acetaminophen or weak opioids (15, 16).

The tendency to avoid opioid use in the treatment of musculoskeletal pain is not justified by published evidence. The expert consensus recommendations for the management of hip and knee OA (OARSI group) deriving from a systematic review of existing guidelines underlines, with high levels of evidence and consensus, that weak opioids can be considered for the treatment of refractory pain, when other pharmacological agents have been ineffective or are contraindicated. In exceptional circumstances stronger opioids could also be prescribed (12). A recent Cochrane review also reported some evidence of efficacy and function improvement in patients treated with opioids for chronic back pain (18). As previously mentioned, weak opioids can be a valid option also in the elderly patients at higher risk for anti-inflammatory-related adverse effects (17).

The American Heart Association lists opioids among medications with a more favourable safety profile, together with acetaminophen, that should be preferred to NSAIDs and particularly coxibs, in patients with coronary artery disease (19). Opioids including tramadol represent a valid option after maximizing non-opioid pain relief strategies also in patients with back pain according to the American Pain Society guidelines (14). Opioids may also be appropriate for patients with neuropathic pain who have not achieved adequate analgesia despite treatment with antineuropathic agents (eg anticonvulsants and tricyclic antidepressants/dual reuptake inhibitors) (14). Two systematic reviews of placebo-controlled trials of opioids for non-cancer pain conditions (mainly OA and neuropathic pain) found opioids to be moderately effective, with a mean decrease in pain intensity with opioids of at least 30% in most trials (20). A meta-analysis of 18 clinical trials in OA patients including a total of 3244 participants treated with opioids demonstrated good efficacy in decreasing pain intensity and conferring modest functional benefits (21).

Great differences exist in analgesic prescription among different European countries. Opioids are prescribed much more readily in Northern Europe compared to the South (including Italy) or the East, leading to the impression that pain treatment seems to be driven mainly by tradition and personal experience rather than by international guidelines (22).

This “opiophobia” can partly be explained by the fear of adverse events induced by opioids. A systematic review and meta-
analysis of 34 trials including 4212 patients provided information on adverse events related to opioid use in treating musculoskeletal pain. About one patient every two experienced at least one adverse event, and one in five discontinued treatment because of adverse events. Nausea (21%), constipation (15%), dizziness (14%), and drowsiness or somnolence (14%) were the most common (23). A recent review on potential adverse effects of long-term opioid therapy (24) confirmed that gastrointestinal (GI) side effects are the most common. Up to 40%-45% of patients on opiate therapy experience constipation, while 25% experience nausea.

Opioid neurotoxicity, dizziness and sedation are a significant issue, especially among the elderly. Other possible adverse reactions are: association between sleep-disordered breathing and chronic opiate use in a dose-dependent fashion, opiate-induced hypogonadism, and possible negative cardiovascular effects such as increased risk of myocardial infarction or heart failure, as well as increased pneumonia risk among the elderly, possibly associated with immunosuppression (24). Tolerance and addiction are also relevant issues when prescribing opioids. Risk factors for opioid abuse are history of previous drug conviction, mental health disorders, past alcohol or illicit drug abuse (25). Moreover, opioid treatment may not be effective because of individual variations to pure μ-opioid agonist therapies and different degrees of central sensitization. In chronic musculoskeletal pain conditions descending inhibitory pain pathways may be disrupted and drugs with different mechanisms of action (eg, serotonin or noradrenaline reuptake inhibition) may be more effective, compared to pure μ-opioid receptor agonists (26-27).

The previous results suggest that efficacy and tolerability problems are encountered with all therapeutic strategies available to treat musculoskeletal pain. This often limits effective analgesia and patients’ long term compliance, with the result that chronic pain is persistently undertreated. The need for new therapeutic options is therefore stringent.

### TAPENTADOL

Tapentadol is a novel, centrally acting analgesic that has been recently commercialized. This new molecule, by combining two distinct mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), introduces a new pharmacological class called MOR-NRI (28). The synergistic interaction of the two combined effects offers particular advantages in terms of efficacy and tolerability. Analgesia is obtained at different levels through modulation of the opioid system and the descending inhibitory noradrenergic systems. The NRI mechanism of action leads to increased noradrenergic activity at the spinal level, through activation of the inhibitory descending pathways where noradrenaline is an important transmitter. The MOR therapeutic effect enhances the action of opioids at the spinal level, where they reduce the transmission of pain signal from the primary afferents to the spinothalamic tract fibers. At a supraspinal level, opioids contribute to activate the descending noradrenergic inhibitory projection to the spinal cord (29). Indeed, several preclinical pain models demonstrate that, despite a 50-fold lower affinity for the MOR, tapentadol is only 2- to 3-fold less potent than morphine, clearly indicating that the NRI component of tapentadol contributes to its analgesic effect in an additive and synergistic manner (30). The two mechanisms of action result in different modulation of acute and chronic pain. The μ-opioid agonism is, in fact, primarily effective in controlling acute pain, whereas noradrenaline reuptake inhibition is mainly implicated in modulating chronic pain (2). The efficacy of tapentadol in neuropathic pain conditions has been demonstrated in a number of experimental models. In this setting, tapentadol shows even higher potency than morphine (ED50 =0.32 mg/kg vs 0.65 mg/kg in diabetic neuropathy) (30). The inhibitory effect on disease-related hyperalgesia suggested a superior efficacy profile of tapentadol compared with classical opioid, including morphine, in a rodent animal model of heat hyperalgesia (31). Efficacy on neuropathic pain has
also been reported in clinical studies, especially in controlling chronic back pain with radicular involvement (32) and diabetic neuropathy (33). The MOR-NRI mechanism of action can finally give advantages in terms of tolerability. Tapentadol’s noradrenergic components has an opioid-sparing effect, thus reducing GI adverse effects compared to traditional opioids. This new molecule also has minimum effect on serotonin reuptake, reducing its effects on the enteric nervous system (constipation, nausea and vomiting) (2). The safety profile is improved by the fact that no relevant interactions with enzymes of the P450 cytochrome system have been registered. The drug binding to plasma protein is low, reducing pharmacokinetic interaction with other medications (2).

Randomized clinical trials (RCT) have consistently demonstrated the efficacy and tolerability of tapentadol prolonged release (PR) (100-250 mg bid) in the management of moderate to severe chronic pain caused by OA and low back pain. (Table I). A meta-analysis on efficacy data (34) was performed using results from 3 RCT of tapentadol PR (100-250 mg bid) compared with placebo and oxycodone controlled release (20-50 mg bid) in the treatment of OA knee pain (35) and chronic low back pain (36). Tapentadol PR analgesic efficacy resulted to be non-inferior to that provided by oxycodone (20-50 mg bid) (p<0.0001), but with a more favourable tolerability profile, particularly regarding GI adverse events (lower rates of nausea, vomiting, constipation) and central nervous system side effects. Also the analyses of 30% and 50% responders, patient global impression of change, Short-Form-36 scores (SF-36) and the EuroQol 5-dimension health status index (EQ-5D) were all significantly improved with tapentadol compared to oxycodone (p≤0.048) (35). Figure 1 and 2.

Comparable results were recently reported by Afilafo et al. (37), confirming the efficacy of tapentadol ER for different types of nociceptive (chronic osteoarthritis knee pain and low back pain) and neuropathic pain (diabetic peripheral neuropathy) over up to one year of treatment, maintaining a better tolerability profile compared to oxydodeone.

Another recent phase 3b study evaluated the effectiveness and tolerability of tapentadol PR, associated with tapentadol immediate release on-demand, for severe chronic OA knee pain, inadequately managed with WHO step I or II analgesics (38). A significant improvement in pain intensity from baseline through week 1 was demonstrated (p<0.0001). Responder rate (the percentage of patients with a decrease in average pain intensity of ≥1 point on a NRS-3 scale: 11-point numerical rating scale ranging 0-10) was 96.9%, associated with high satisfaction ratings. All the subscale scores and the global score of the WOMAC (Western Ontario and McMaster Universities osteoarthritis index), a self-administered questionnaire used to assess pain, disability and joint stiffness in knee and hip OA, significantly improved from baseline to weeks 6, 8, and 12. Quality of life was also improved by tapentadol treatment, as demonstrated by significantly improved scores in the EQ-5D and SF-36 physical and mental components. Significant reduction of anxiety and depression reported by patients were also recorded (39). Side effects were reported by 71% of patients (leading to study discontinuation in 12.5% of patients). The majority of adverse events (95.7%) were considered to be of mild or moderate intensity, mainly affecting the GI system (39).

Tapentadol proved to be effective also in the management of neuropathic pain in the setting of severe chronic low back pain that was inadequately managed with WHO step I and II analgesics (39). Significant improvements in pain intensity and neuropathic pain symptoms have been observed on an open-label, phase 3 study analyzing the effect of tapentadol vs strong opioids in the management of chronic low back pain (33). Patients responding to WHO step III opioids, but with scarce tolerability, were selected to receive tapentadol PR. Pain relief was comparable to equianalgesic doses of strong opioids, but with improved tolerability. Neuropathic pain component of low back pain was as-
<table>
<thead>
<tr>
<th>Author, year</th>
<th>Type of study</th>
<th>No.</th>
<th>Cause of chronic pain</th>
<th>Control group</th>
<th>Study period</th>
<th>Results</th>
<th>Discontinuation due to AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afifafo, 2010*</td>
<td>Multicentre, double blind, phase III</td>
<td>1023</td>
<td>OA knee pain</td>
<td>Oxycodone, placebo</td>
<td>15 wks</td>
<td>≥50% improvement of pain intensity in 32% for TP PR vs 24.3% for OX CR (p=0.027)</td>
<td>19.2% TP PR vs 42.7% OX CR (GI 43% vs 67.3%)</td>
</tr>
<tr>
<td>NCT00486811*</td>
<td>Double blind randomized phase III</td>
<td>987</td>
<td>OA knee pain</td>
<td>Oxycodone, placebo</td>
<td>15 wks</td>
<td>Differences in reduction of pain intensity not statistically significant between TP PR, OX CR and placebo</td>
<td>18.8% TP PR vs 40.7% OX CR</td>
</tr>
<tr>
<td>Buynak, 2010*</td>
<td>Prospective, randomized, double-blind, phase III study</td>
<td>981</td>
<td>OA knee pain</td>
<td>Oxycodone, placebo</td>
<td>15 wks</td>
<td>Reduction in pain intensity (-2.9 for TP PR and OX CR vs -2.1 for placebo) p&lt;0.001</td>
<td>16.7% TP PR vs 31.7% OX CR (GI 43.7% vs 61.9% OX CR)</td>
</tr>
<tr>
<td>Wild, 2010</td>
<td>Open label, phase III</td>
<td>1117</td>
<td>OA knee or hip pain and LBP</td>
<td>Oxycodone</td>
<td>52 wks</td>
<td>Sustained long-term efficacy</td>
<td>22.1% TP PR vs 36.8% OX CR (GI 8.6% vs 21.5%)</td>
</tr>
<tr>
<td>Steigerwald, 2012</td>
<td>Open-label, phase IIIb</td>
<td>224</td>
<td>OA knee pain</td>
<td>WHO step I or II analgesics</td>
<td>7 wks</td>
<td>Responders rate: 96.9%</td>
<td>12.5% (nausea, constipation)</td>
</tr>
<tr>
<td>Gálvez, 2013</td>
<td>Multicenter, multinational, open-label, phase IIIb</td>
<td>342</td>
<td>Chronic back pain (+/-neuropathic) with poor tolerability to previous opioids</td>
<td>Strong opioids</td>
<td>12 wks</td>
<td>Responders rate: 80.9%</td>
<td>14.4% (nausea, vomiting, dizziness)</td>
</tr>
<tr>
<td>Baron, 2015</td>
<td>Multicenter, multinational, open-label, phase IIIb</td>
<td>288</td>
<td>LBP with a neuropathic component</td>
<td>TP PR lower dose + Pregabalin</td>
<td>8 wks</td>
<td>Effectiveness non inferior to control group</td>
<td>51% (serious AE 3.2% vs 1.9%)</td>
</tr>
<tr>
<td>Baron, 2015</td>
<td>Multicenter, open label, phase IIIb trial, continuation arm</td>
<td>309</td>
<td>LBP with a neuropathic component having reached pain control with TP PR 300 mg/day (continuation arm)</td>
<td>TP 500 mg/day or TP PR + pregabalin (comparative arm) for patients who had not adequately responded to TP PR 300 mg/day</td>
<td>8 wks</td>
<td>Mean pain intensity improved (mean change: -5.3 for TP PR arm; -2.5 comparative arm)</td>
<td>50.8%, leading to discontinuation in 5.1% (nausea, vomiting, headache, nervousness, restlessness)</td>
</tr>
</tbody>
</table>

sessed using the painDETECT questionnaire or the Neuropathic Pain Symptom Inventory (NPSI). PainDETECT is a highly sensitive tool that addresses frequency and quality of neuropathic pain symptoms, pain patterns over time and radiating pain (33, 40). The Neuropathic Pain Symptom Inventory (NPSI) is a validated measure addressing different qualities of spontaneous, ongoing or paroxysmal pain, evoked pain and dysesthesia or paresthesia together with frequency and duration of pain (33, 41). Both painDETECT and NPSI significantly improved with tapentadol treatment. In line with previous studies, also measures of quality of life, health status, function and patient satisfaction increased substantially (33). In 2015, a Cochrane review analysed the available evidence concerning the use of Tapentadol for chronic musculoskeletal

Figure 1 - Patient global impression of change at endpoint. Statistically significant difference of Patient Global Impression of Change for tapentadol and oxycodone compared to placebo (p<0.001). Modified from Lange et al. (34).

Figure 2 - Treatment emergent adverse events. Data from Pooled analysis by Lange et al (34). Significant lower incidence of GI adverse events in the tapentadol group compared to oxycodone (p<0.001). Gastroint. = gastrointestinal side effects.
pain in adults. The authors included data on 4094 patients with LBP and/or OA enrolled in several RCTs. All trials were oxycodone-controlled and sometimes accepted the use of placebo. When compared to placebo, TP PR demonstrated a mean reduction of 0.56 points (95% CI 0.92-0.2) on a 11-point-NRS scale at 12 weeks of follow up, with a 36% probability of responding to treatment. The risk of discontinuation due to side effects during treatment with TP PR increased of 2.7 fold. In the oxycodone-controlled analyses, TP PR showed a 0.24 points (95% CI 0.43-0.05) reduction in pain intensity. The possibility to respond to treatment did not reach statistical significance. The high heterogeneity of the efficacy estimates may account for some of the suboptimal results. Nevertheless, TP PR confirmed the good tolerability profile with a 50% reduction in the risk of discontinuation due to side effects and a 9% reduction in the overall adverse events occurrence risk compared to oxycodone (42).

Ongoing studies with promising results are also exploring the use of Tapentadol in the management of fibromyalgia not responding to standard therapy. Long term safety of tapentadol in the treatment of chronic OA and low back pain has been evaluated for up to one year in a Phase III, open-label, randomized study including 1117 patients (43). Patients were randomized 4:1 to receive tapentadol PR or oxycodone CR. Tapentadol provided stable, long-term relief from chronic pain and was associated with significantly lower levels of constipation (22.6% vs 38.6%; p<0.001), nausea (18.1% vs 33.2%; p<0.001), and vomiting (7.0% vs 13.5%; p=0.002) compared to oxycodone. GI side effects led to study discontinuation in 8.6% and 21.5% of patients respectively (44). Tapentadol also showed minimal effects on adrenal, pituitary, hypothalamic and gonadal hormone production with lower rates of opioid-induced androgen deficiency compared to other μ-opioid analgesics (2).

CONCLUSIONS

Musculoskeletal conditions are the most frequent cause of chronic pain and affect around 1 in 5 adults in Europe. When chronic pain occurs, it becomes disease itself, with substantial clinical, psychological, social and economic impact. Pain is too often underestimated and inadequately treated; this is mainly due to tolerability problems connected with traditional analgesics and unjustified low prescription rates of opioids. Recently Tapentadol, a novel, centrally acting analgesic has been introduced for the treatment of chronic pain. This new molecule, by combining two distinct mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), introduces a new pharmacological class called MOR-NRI. Tapentadol has shown promising results in the management of both nociceptive and neuropathic pain and good tolerability profile, particularly concerning GI side effects, compared to traditional opioids. Several studies have led to consistent and reproducible results on efficacy and tolerability profile of tapentadol, regardless of the type of chronic pain, study population, and methodological differences. This versatility is enabled by a molecule without active metabolites and a double mechanisms of action. This novel analgesic represents a possible therapeutic option also in the rheumatologic field, particularly in the treatment of osteoarthritis and low back
pain. Further studies are needed to assess the role of tapentadol in the management of pain connected with inflammatory arthritis or caused by vasculitis.

**REFERENCES**